Alto Neuroscience, Inc. insider trading
Every open-market purchase and sale by Alto Neuroscience, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Alto Neuroscience, Inc.’s insiders pay?
From April 1, 2024 to July 11, 2024, 2 insiders reported 2 open-market purchases and 0 sales not made under a pre-set plan in Alto Neuroscience, Inc. Twelve months after each purchase was reported, the shares were −92.8% against the S&P 500 on average (median −92.8%), over 2 purchases with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on April 2, 2024 into $1,999 by November 2, 2026, −46.5% a year. It held shares 49% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $12,872 (+10.3% a year), and held throughout $15,011 (+17.1%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Savitz Adam | CHIEF MEDICAL OFFICER | 1 | −93.9% (1) | 0% | 0 | — | July 11, 2024 |
| Smith Nicholas Conrad | CHIEF FINANCIAL OFFICER | 1 | −91.7% (1) | 0% | 0 | — | April 1, 2024 |